A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Roberto Rodriguez, Ryotaro Nakamura, Joycelynne M. Palmer, Pablo Parker, Sepideh Shayani, Auyaporn Nademanee, David Snyder, Vinod Pullarkat, Neil Kogut, Joseph Rosenthal, Eileen Smith, Chatchada Karanes, Margaret O'Donnell, Amrita Y. Krishnan, David Senitzer and Stephen J. Forman
This article has an Erratum 115(21):4318

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
Publication Date - String
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

  • Impact of preparative regimen on microangiopathy during m-TOR inhibitor based GVHD prophylaxis
    • Uwe Platzbecker, Hematologist
    • Other Contributors:
      • Gerhard Ehninger, Martin Bornh�user

    With interest we read the study by Rodriguez and colleagues demonstrating a considerable incidence of thrombotic microangiopathy (TMA) in patients receiving a combination of sirolimus with tacrolimus as GVHD prophylaxis after allogeneic HCT (1). In accordance with other reports these data are suggestive that pharmacological m-TOR inhibition increases the overall risk of TMA (2,3). Interestingly, the overall rate signif...

    Show More
    Conflict of Interest:
    None declared.